• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Methodology and Instructions

Methodology and Instructions Although the general principles for the development of breakpoints are similar to those for bacteria, susceptibility testing of fungi needs special attention. This page lists the documents that address the methods needed for testing of different fungi. AST of Yeasts…

Get to know more

Rapid AST in blood culture

Rapid AST in blood culture For selection of an efficacious antibiotic therapy rapid susceptibility results are desirable, but the usual overnight incubation precludes rapid results. EUCAST RAST fills this gap by providing results within 4 to 8 hours of incubation. The method is validated for…

Get to know more

ECOFFinder software removed from the EUCAST website

ECOFFinder. The previously available ECOFFinder software is no longer accessible on the EUCAST website because, according to EUCAST procedures ( SOP 10.2), setting ECOFFs or TECOFFs on single or already aggregated distributions is not acceptable according to EUCAST recommendations. Software and…

Get to know more

Colistin susceptibility testing

A few weeks ago, we informed EUCAST users, that the Warning against bioMerieux AST material for colistin, still stands. The item referred (by a link) to the EUCAST Warnings page where it was made clear exactly which material was malfuntioning and should have been withdrawn by bioMerieux. However,…

Get to know more

General Committee Meetings

General Committee Meetings The EUCAST yearly General Committee meetings are open meetings, held during yearly ESCMID-Global conferences. Everyone interested in breakpoints and AST methods are welcome. Meeting minutes EUCAST General Committee meeting 2024 (ECCMID, Barcelona) EUCAST General Committee…

Get to know more

Information for industry - reference and standardised AST.

EUCAST guidance on how to determine MIC values and develop distributions (and zone diameter distributions) for new agents in preparation for EUCAST and EMA evaluation. The development of new agents requires agreement and acceptance of the data generated in support of decisions on clinical…

Get to know more

Rationale Documents

Rationale Documents The EUCAST Rationale Documents currently available are listed below. Rationale documents for antifungal agents are listed elsewhere, see " Antifungal rationale documents ". A template for companies aiming to create a comprehensive rationale document for new agents or for existing…

Get to know more

S, I and R and surveillance of AMR

This is to clarify how "susceptibility (S and I)" and "resistance (R)" should be reported in AMR surveillance with the EUCAST definitions of S I and R . With the EUCAST definitions, the tradition to report "non-susceptibility" as the joint rate of %I and %R is abandoned. Previously (pre-2019) it was…

Get to know more

Resistance Detection in RAST

Resistance Detection in RAST Some resistance mechanisms require other than clinical breakpoints for sensitive detection. EUCAST has validated using separate screening cut-offs for the detection of E. coli and K. pneumoniae with ESBL or carbapenemases. Screening for resistance mechanisms using RAST…

Get to know more

Publications and Presentations

Publications and Presentations 2025 2023 2022 2020 Archive The Mycobacterium tuberculosis complex based on the EUCAST reference protocol. Mansjö M, Espinosa-Gongora C, Samanci I, Groenheit R, Werngren J. Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0094624. doi: 10.1128/aac.00946-24. Epub 2024…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here